News & Perspective

Jun 12, 2008

Jun 12, 2008

Baxter says cell-based H5N1 vaccine did well in trial

(CIDRAP News) – A pharmaceutical company is reporting good results in the first clinical trial of an H5N1 avian influenza vaccine that uses a whole, killed H5N1 virus grown in cell culture—a combination of techniques that entails some risk but may boost immune response and shorten production time.

Nov 15, 2007

Nov 15, 2007

THE PANDEMIC VACCINE PUZZLE Can we vaccinate enough people in time to matter?

Maryn McKennaContributing Writer

(CIDRAP News) – This in-depth article investigates the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. Its seven parts put advances in vaccine technology in perspective by illuminating the formidable barriers to producing an effective and widely usable vaccine in a short time frame.

Oct 17, 2006

Oct 17, 2006

Baxter says cell-based H5N1 vaccine shows potential in trial

(CIDRAP News) – Low doses of a cell-based avian flu vaccine triggered a good immune response to the H5N1 avian influenza virus, according to preliminary results of a clinical trial by Baxter International of Deerfield, Ill., maker of the vaccine.

Jan 05, 2006

Jan 05, 2006

YEAR-END REVIEW: Avian flu emerged as high-profile issue in 2005

Jan 6, 2006 (CIDRAP News) – 2005 is likely to go down as the year when avian influenza, powered by a steady rise in human cases and the spread of poultry outbreaks all the way to Eastern Europe, emerged as a high-profile global health issue.

When 2005 dawned, only 45 human cases of H5N1 avian flu, including 32 deaths, had been counted by the World Health Organization (WHO). All of those were in Vietnam and Thailand.

Sort Results By:

 Sort Results By:

Narrow results by:

Newsletter Sign-up

Get CIDRAP news and other free newsletters.

Sign up now»

OUR UNDERWRITERS

Unrestricted financial support provided by

Bentson Foundation 3MAccelerate DiagnosticsGilead 
Grant support for ASP provided by


bioMérieux

  Become an underwriter»